Publication | Closed Access

Efficacy of an Ondansetron Orally Disintegrating Tablet: A Novel Oral Formulation of this 5-HT3 Receptor Antagonist in the Treatment of Fractionated Radiotherapy-Induced Nausea and Emesis

OncologyRadiation TherapyMedicine5-Ht3 Receptor AntagonistRadiopharmaceutical TherapyFractionated Radiotherapy-induced NauseaPharmacotherapyPharmacologyRadiation OncologyNovel Oral Formulation